In order to evaluate the potential role of circulating LGALS3BP as biomarker for GBM, serum‐derived EVs from healthy donors and GBM patients before surgery were isolated using a polymer‐based methodology, and purified EVs were characterized by WB and ELISA (Fig. S1A,B). This evidence concerns the gene LGALS3BP and glioblastoma.